Available data on i.v. Mark T. Holdsworth, Pharm.D., BCOP, Phuongthao Nguyen, PHARM.D., Role of i.v. The primary advantage of i.v. Allopurinol blocks the conversion of xanthines to uric acid, so this will reduce the effect of rasburicase; therefore DO NOT give allopurinol and rasburicase together. While using rasburicase, you may need frequent blood tests. dialysis In general, there is a low threshold for dialysis, because this will resolve numerous problems encountered in tumor lysis syndrome. The primary advantage of i.v. Nat Clin Pract Rheumatol. allopurinol is the flexibility of administration for patients who cannot take anything by mouth, since there are no data indicating the superiority of the i.v. Sequential therapy with rasburicase and allopurinol did not significantly improve the response rate compared with single-agent allopurinol (78% vs. 66%; p = 0.06). Allopurinol might be considered in patients who cannot receive rasburicase (due to allergy or G6PD deficiency). In a phase 3 trial, ELITEK given prophylactically (prior to anticancer therapy) maintained normal uric acid levels (≤7.5 mg/dL) in significantly more high-risk patients (89%, n=82) vs allopurinol (68%, n=85) between 3 and 7 days after initiation of antihyperuricemic treatment (P=0.001). Epub 2017 Jun 15.J Adv Res. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwideFor full access to this pdf, sign in to an existing account, or purchase an annual subscription. This article is also available for rental through DeepDyve. 1-3Results were consistent with the overall study population (primary endpoint): 87% (n=92) of … to the oral product.Rasburicase is the first agent that will oxidize uric acid to allantoin, a metabolite with 5-10-fold greater solubility than uric acid, and reduces serum uric acid (SUA) levels within four hours of administration. Oxford University Press is a department of the University of Oxford. 2006 Jun;2(6):338-42; quiz 343. doi: 10.1038/ncprheum0214.Tausche AK, Christoph M, Forkmann M, Richter U, Kopprasch S, Bielitz C, Aringer M, Wunderlich C.Rheumatol Int.
HighWire Rasburicase could be useful for patients with gout that is unresponsive to allopurinol or who cannot tolerate the therapy. All treatment failures (11%) occurred in the single-agent allopurinol arm. Search for other works by this author on:
Patients receiving rasburicase were propensity score matched to allopurinol-treated patients in a 1:4 ratio based on time between hospital admission and treatment initiation, baseline UA level, cancer type, age, gender, race, hospital characteristics, payer type, and prior intensive-care unit (ICU) admission. This content is only available as a PDF. 2018 Oct 18;10:141-149. doi: 10.2147/OARRR.S176951. Unable to load your delegates due to an error allopurinol and rasburicase became available for the management of TLS.
Preliminary evidence indicates that rasburicase offers cost savings in the treatment of TLS and is cost-effective as a strategy for preventing TLS for many cancer patients.Both i.v. Rasburicase is considerably more expensive than standard management strategies and should be reserved for patients with either renal dysfunction, significant elevations in SUA values, or large tumor burdens. Objective: To evaluate the short-term safety and outcome of 2 different experimental applications of rasburicase 0.2 mg/kg (monthly vs daily) in patients with tophaceous gout not treatable by allopurinol. 2014 Sep;92:48-54. doi: 10.3899/jrheum.140462.Int J Med Sci.